Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genomics.com

Genomics stock continued their internet-like advances over the holidays, with investors starting to look down into the lower tier of companies for genomics plays that had not yet moved.

Leading the pack was Genome Therapeutics (GENE), which soared $11.188 (186 percent) to $17.188 on Christmas week on news of achieving a milestone in its asthma genomics deal with Schering-Plough and announcing a $118 million osteoporosis deal with Wyeth-Ayerst. GENE lost $1.063 to $16.125 last week.

Investors also discovered Lynx (LYNX), which added $17.25 (96 percent) to $35.25 on Christmas week before retreating $2.875 to $32.375 last week. Myriad (MYGN) enjoyed a two-week gain, adding $11 (33 percent) to $44 on Christmas week, and another $2 to $46 last week.

Celera (CRA) surged $56 (64 percent) to $144 on Christmas week on minimal news: it purchased gene and protein identification software from Molecular Applications (see B3). Street talk was that trading was driven by The Motley Fool's announcement that CRA had been added to the "rule breaker" portfolio of the popular stock market web site. CRA added $5 to $149 last week.

Incyte (INCY) finally closed at $60 on Friday, posting an $8.438 (16 percent) gain on the week, after jumping as high as $73.125 on the Wednesday before Christmas. Driving demand was news that INCY had identified mutations in

Read the full 2179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE